Erratum: Whole Genome and Transcriptome Sequencing of Matched Primary and Peritoneal Metastatic Gastric Carcinoma

J. Zhang,J. Y. Huang,Y. N. Chen,F. Yuan,H. Zhang,F. H. Yan,M. J. Wang,G. Wang,M. Su,G Lu,Y. Huang,H. Dai,J. Ji,J. N. Zhang,Y. N. Jiang,S. J. Chen,Z. G. Zhu,Y. Y. Yu
DOI: https://doi.org/10.1038/srep15309
IF: 4.6
2015-01-01
Scientific Reports
Abstract:Gastric cancer is one of the most aggressive cancers and is the second leading cause of cancer death worldwide. Approximately 40% of global gastric cancer cases occur in China, with peritoneal metastasis being the prevalent form of recurrence and metastasis in advanced disease. Currently, there are limited clinical approaches for predicting and treatment of peritoneal metastasis, resulting in a 6-month average survival time. By comprehensive genome analysis will uncover the pathogenesis of peritoneal metastasis. Here we describe a comprehensive whole-genome and transcriptome sequencing analysis of one advanced gastric cancer case, including non-cancerous mucosa, primary cancer and matched peritoneal metastatic cancer. The peripheral blood is used as normal control. We identified 27 mutated genes, of which 19 genes are reported in COSMIC database (ZNF208, CRNN, ATXN3, DCTN1, RP1L1, PRB4, PRB1, MUC4, HS6ST3, MUC17, JAM2, ITGAD, IREB2, IQUB, CORO1B, CCDC121, AKAP2, ACAN and ACADL), and eight genes have not previously been described in gastric cancer (CCDC178, ARMC4, TUBB6, PLIN4, PKLR, PDZD2, DMBT1and DAB1).Additionally,GPX4 and MPND in 19q13.3-13.4 region, is characterized as a novel fusion-gene. This study disclosed novel biological markers and tumorigenic pathways that would predict gastric cancer occurring peritoneal metastasis.
What problem does this paper attempt to address?